Drug Profile
Potassium dobesilate topical - DermAct Pharmaceutical
Alternative Names: 2,5-Dihydroxybenzenesulfonic-acid-monopotassium-salt; AM-001; Potassium-2,5-dihydroxybenzenesulfonateLatest Information Update: 28 Dec 2022
Price :
$50
*
At a glance
- Originator DermAct Pharmaceutical
- Developer AmDerma Pharmaceuticals; DermAct Pharmaceutical
- Class Benzenesulfonates; Potassium compounds; Skin disorder therapies; Small molecules
- Mechanism of Action Fibroblast growth factor inhibitors; Fibroblast growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Plaque psoriasis
- Discontinued Actinic keratosis
Most Recent Events
- 28 Dec 2022 Discontinued - Phase-II for Actinic keratosis in USA (Topical)
- 28 Dec 2022 Discontinued - Phase-II for Plaque psoriasis in USA (Topical)
- 17 Sep 2020 No development reported - Phase-II for Actinic keratosis in USA (Topical)